What's in Fondazione Italiana Linfomi - ETS's pipeline?

Fondazione Italiana Linfomi - ETS has 24 drugs in our index: 2 marketed, 0 filed, 11 in Phase 3, 11 in Phase 2, 0 in Phase 1.

Which companies overlap with Fondazione Italiana Linfomi - ETS's portfolio?

Top competitors by shared drug class: Universität des Saarlandes, American Scitech International, Azienda Ospedaliera Universitaria Integrata Verona, Arbeitsgemeinschaft medikamentoese Tumortherapie, AryoGen Pharmed Co..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fondazione-italiana-linfomi-ets.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fondazione Italiana Linfomi - ETS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fondazione Italiana Linfomi - ETS pipeline: 2 marketed, 0 filed, 11 Phase 3, 11 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 11 Phase 3 11 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
R-CVP	R-CVP	marketed			Other
Treatment plan	Treatment plan	marketed	Monoclonal antibody	CD20	Oncology
Doxorubicina	Doxorubicina	phase 3			Other
R-CHOP or R-bendamustine	R-CHOP or R-bendamustine	phase 3	Monoclonal antibody + chemotherapy combination	CD20 (rituximab component)	Oncology
R2-MANT	R2-MANT	phase 3		CD20 (presumed, based on rituximab component)	Oncology
Vincristina	Vincristina	phase 3			Other
Ibritumomab Tiuxetan + Maintenance	Ibritumomab Tiuxetan + Maintenance	phase 3	Radiolabeled monoclonal antibody (anti-CD20)	CD20	Oncology
R-FM	R-FM	phase 3	Chemoimmunotherapy regimen	CD20	Oncology
R-MANT	R-MANT	phase 3	Monoclonal antibody + chemotherapy combination	CD20	Oncology
RCHOP o R-miniCHOP at standard doses	RCHOP o R-miniCHOP at standard doses	phase 3	CD20-targeting monoclonal antibody in combination with chemotherapy	CD20	Oncology
Standard Maintenance	Standard Maintenance	phase 3			Oncology
Maintenance weekly x4	Maintenance weekly x4	phase 3	Monoclonal antibody	CD19	Oncology

Therapeutic area mix

Oncology · 13
Other · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Universität des Saarlandes · 2 shared drug classes
American Scitech International · 1 shared drug class
Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
AryoGen Pharmed Co. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Amgen · 1 shared drug class
Alexion Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fondazione Italiana Linfomi - ETS:

Cite this brief

Drug Landscape (2026). Fondazione Italiana Linfomi - ETS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fondazione-italiana-linfomi-ets. Accessed 2026-05-17.